The global benign uterine conditions therapy systems market is expected to display attractive growth in forthcoming period. Endometriosis is a converse condition found in women whereby menstrual blood flows back into the pelvic cavity instead of leaving the body. Endometriosis is a benign health condition in women where the lining of the uterus grows out of the uterine cavity. The tissue is then shed during menstruation.
The tissue that grows outside the uterine cavity is called endometrial implants. Endometriosis could occur in fallopian tubes, ovaries, pelvic cavity, vagina, cervix and bladder. Rarely has it been witnessed on other parts of the body such as lungs, brain or skin. Women of reproductive age often have this condition. The growth factors for benign uterine conditions therapy systems market are that amongst a large percentage of women, uterine fibroids come without any indication or are rather asymptomatic and more often go undetected.
The menstrual blood forms a thick layer over the surface of the bladder, ovaries or rectum and this continue to exaggerate over the course of each menstrual cycle. Segmentation of benign uterine conditions therapy systems industry by product includes endometrial ablation devices, magnetic resonance-guided high-intensity focused ultrasound systems, uterine artery embolization systems and hysteroscopes and related products. Segmentation of benign uterine conditions therapy systems market by major applications/end users includes hysterectomy, hysteroscopy, myomectomy and dilation and curettage.
Segmentation of benign uterine conditions therapy systems market by geographical regions includes North America, Europe, Asia Pacific, MEA and Latin America. Uterine fibroids are benign, monoclonal tumors of the smooth muscle cells found in human uterus. Uterine fibroids are the most common benign tumors in women and are the leading cause for hysterectomies in USA. Medical screening tests and sonography tests were undertaken to determine the presence of uterine fibroids. The key industry players in benign uterine conditions therapy systems market include Celenova Biosciences, Inc., Philips Healthcare, Hologic Inc., Smith and Nephew PLC, Johnson and Johnson, Boston Scientific Corporation and Karl Storz GmbH and Co. KG.
Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Benign Uterine Conditions Therapy Systems in these regions, from 2012 to 2022 (forecast), covering
• North America
• Southeast Asia
Global Benign Uterine Conditions Therapy Systems market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
• CeloNova Biosciences, Inc.
• Hologic, Inc.
• InSightec LTD/Elbit Imaging LTD
• Johnson & Johnson
• Philips Healthcare
• Smith & Nephew PLC
• Boston Scientific Corporation
• KARL STORZ GmbH & Co. KG
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
• Endometrial Ablation Devices
• Magnetic Resonance-Guided High-Intensity Focused Ultrasound Systems
• Uterine Artery Embolization Systems
• Hysteroscopes And Related Products
On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including
• Dilation and Curettage
Research Support Specialist, USA